Skip to content

A Study on Brain Imaging and Blood Biomarkers of Non-invasive Neuromodulation Therapy for Depression Patients

A Study on Brain Imaging and Blood Biomarkers of Non-invasive Neuromodulation Therapy for Depression Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113973
Enrollment
Unknown
Registered
2025-12-04
Start date
2024-09-12
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Interventions

SSRI control group:Take citalopram as an example. Take it orally every day for 4 weeks, starting at 20 mg/day. If the HAMD-17 score doesn’t decrease by 50%, increase the dose by 20 mg every 2 - 4 week
SSRI+rTMS treatment group:The TMS protocol will adhere to the consensus recommendations of the NNDC TMS Task Force and the APA CoR Novel Biomarkers and Treatments Task Force. USFDA - approved paramete
SSRI+MECT treatment group:MECTA spECTrum 5000Q device will be used at 800 milliamperes. The seizure threshold for each patient will be determined via stimulus titration. Under right unilateral setup,

Sponsors

The Affiliated Kangning Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age: 13--70 years old. 2. Education: At least junior high school level, able to read and understand documents like the informed consent form and self - assessment scales independently. 3. Diagnosis: Patients diagnosed with depression based on ICD - 10 criteria. 4. Contraception: Women of childbearing potential must use two contraceptive methods, confirmed by the research team. 5. Participation consent: Patients and their family members agree to participate in the project and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed with schizophrenia, bipolar disorder, personality disorders, or other severe mental illnesses per ICD-10. 2. History of alcohol or drug abuse. 3. Severe neurological diseases, such as epilepsy, stroke, or brain tumors. 4. History of severe head injury with neurological sequelae. 5. Patients with severe physical, infectious, or immune system diseases. 6. Contraindications for MRI, including pregnancy/breastfeeding, cardiac pacemakers, cerebral aneurysm clips, ferromagnetic implants, artificial metal heart valves, metal joints, or insulin pumps/nerve stimulators.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale score;

Secondary

MeasureTime frame
Hamilton Anxiety Scale score;

Countries

China

Contacts

Public ContactTiansheng Zheng

The Affiliated Kangning Hospital of Wenzhou Medical University

andan1127@163.com+86 137 7779 7647

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026